The role of collateral related donors in haploidentical hematopoietic stem cell transplantation

被引:27
|
作者
Mo, Xiao-Dong [1 ]
Zhang, Yuan-Yuan [1 ]
Zhang, Xiao-Hui [1 ]
Xu, Lan-Ping [1 ]
Wang, Yu [1 ]
Yan, Chen-Hua [1 ]
Chen, Huan [1 ]
Chen, Yu-Hong [1 ]
Chang, Ying-Jun [1 ]
Liu, Kai-Yan [1 ]
Huang, Xiao-Jun [1 ,2 ,3 ]
机构
[1] Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
[2] Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China
[3] Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
基金
中国国家自然科学基金;
关键词
Haploidentical; Hematopoietic stem cell transplantation; Collateral related donors; Paternal donors; Maternal donors; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; IDENTICAL-SIBLING TRANSPLANT; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHRONIC GRAFT; HEMATOLOGICAL MALIGNANCIES; UNRELATED DONORS; SINGLE-CENTER; RISK-FACTORS;
D O I
10.1016/j.scib.2018.08.008
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A key issue in the haploiedntical hematopoietic stem cell transplantation (haplo-HSCT) setting is the search for the best donor, because donor selection can significantly impact the clinical outcomes. We aimed to identify the role of collateral related donors (CRDs) in donor selection for haplo-HSCT through comparing the clinical outcomes between CRDs (n = 60) and maternal donors (MDs, n = 296), which were the last choice of donor selection in immediate related donors (IRDs). The cumulative incidence of graft-versus-host disease was comparable between CRDs and MDs. The 5-year cumulative incidence of relapse and non-relapse mortality was 22.0% (95% CI, 11.3%-32.7%) versus 17.4% (95% CI, 13.0%-21.8%) (P = 0.455) and 25.0% (95% CI, 13.9%-36.1%) versus 23.1% (95% CI, 18.2%-28.0%) (P = 0.721) for the CRDs and MDs, respectively. The 5-year probabilities of disease-free survival and overall survival was 53.2% (95% CI, 40.4%-66.0%) versus 59.5% (95% CI, 53.8%-65.2%) (P = 0.406) and 56.5% (95% CI, 43.8%-69.2%) versus 61.8% (95% CI, 56.1%-67.5%) (P = 0.458) for the CRDs and MDs, respectively. Female donor/male recipient (FDMR) CRDs were associated with the poorest clinical outcomes, and the clinical outcomes of non-FDMR CRDs were comparable to those of MDs. In summary, our results showed that CRDs did not showed superiority over MDs. Thus, IRDs should be the first choice of donor selection, and CRDs could only be the donors for those without IRDs. (C) 2018 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.
引用
收藏
页码:1376 / 1382
页数:7
相关论文
共 50 条
  • [41] Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients
    Huang, Xiao-Jun
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2011, 24 (03) : 351 - 358
  • [42] Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies
    Zaghi, Elisa
    Calvi, Michela
    Di Vito, Clara
    Mavilio, Domenico
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [43] Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies
    Ma, Rui
    Huang, Xiao-Jun
    Xu, Lan-Ping
    Liu, Kai-Yan
    Zhang, Xiao-Hui
    Yan, Chen-Hua
    Han, Wei
    Wang, Feng-Rong
    Chen, Yu-Hong
    Chen, Huan
    Chen, Yao
    Wang, Jing-Zhi
    Wang, Yu
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (06) : 1210 - 1217
  • [44] Haploidentical parental hematopoietic stem cell transplantation in pediatric refractory Langerhans cell histiocytosis
    Jun, Yang
    Quan, Qin Mao
    Bin, Wang
    Hua, Zhu Guang
    Li, Zhang
    Rui, Zhang
    Guang, Jia Chen
    Hao, Ma Hong
    Long, Duan Yan
    Jing, Yang
    Xuan, Zhou
    PEDIATRIC TRANSPLANTATION, 2014, 18 (04) : E124 - E129
  • [45] Recent Advances in Haploidentical Stem Cell Transplantation
    Alpdogan, Onder
    Grosso, Dolores
    Flomenberg, Neal
    DISCOVERY MEDICINE, 2013, 16 (88) : 159 - 165
  • [46] Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation
    Liu, Jiangying
    Xu, Lan-Ping
    Bian, Zhilei
    Chang, Ying-Jun
    Wang, Yu
    Zhang, Xiao-Hui
    Huang, Xiao-Jun
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [47] Allogeneic hematopoietic stem cell transplantation in elderly
    Castagna, Luca
    Blaise, Didier
    Furst, Sabine
    BULLETIN DU CANCER, 2011, 98 (08) : 915 - 925
  • [48] The role of natural killer cells in hematopoietic stem cell transplantation
    Tsirigotis, Panagiotis D.
    Resnick, Igor B.
    Shapira, Michael Y.
    ANNALS OF MEDICINE, 2012, 44 (02) : 130 - 145
  • [49] Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed Metastatic Retinoblastoma
    Rastogi, Neha
    Kapoor, Rohit
    Yadav, Satya P.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2020, 42 (08) : 499 - 499
  • [50] Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation
    Wu, Hengwei
    Cai, Zhen
    Shi, Jimin
    Luo, Yi
    Huang, He
    Zhao, Yanmin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (06): : 3111 - 3122